A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Plaque Psoriasis

In brief

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

Key facts

Study ID

NCT06143878

Run by

Janssen Research & Development, LLC

People needed

774

Starts

2024-02-01

Expected to finish

2027-06-01

Last updated by the study team

2026-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention
• Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
• Total psoriasis area and severity index (PASI) >=12 at screening and baseline
• Total investigator global assessment (IGA) >=3 at screening and baseline
• Candidate for phototherapy or systemic treatment for plaque psoriasis

You may not qualify if…

• Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
• Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
• A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
• Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib, or to any of the excipients or components of the study intervention
• Major surgical procedure, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study

Where it is running

• Center for Dermatology and Plastic Surgery — Scottsdale, Arizona, United States
• Johnson Dermatology — Fort Smith, Arkansas, United States
• First OC Dermatology — Fountain Valley, California, United States
• Center for Dermatology Clinical Research — Fremont, California, United States
• Integrative Skin Science and Research — Sacramento, California, United States
• Southern California Dermatology — Santa Ana, California, United States
• Clinical Science Institute — Santa Monica, California, United States
• Driven Research LLC — Miami, Florida, United States
• Ziaderm Research LLC — North Miami Beach, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• Forcare Clinical Research Inc — Tampa, Florida, United States
• Hamilton Research LLC — Alpharetta, Georgia, United States
• Skin Care Physicians of Georgia — Macon, Georgia, United States
• DeNova Research — Chicago, Illinois, United States
• Arlington Dermatology — Rolling Meadows, Illinois, United States
• Endeavor Health — Skokie, Illinois, United States
• Dundee Dermatology — West Dundee, Illinois, United States
• Dawes Fretzin Clinical Research Group LLC — Indianapolis, Indiana, United States
• Indiana Clinical Trial Center — Plainfield, Indiana, United States
• Dermatology Specialists — Louisville, Kentucky, United States
• Dermatology and Advanced Aesthetics — Lake Charles, Louisiana, United States
• Tufts Medical Center — Boston, Massachusetts, United States
• David Fivenson MD, Dermatology — Ann Arbor, Michigan, United States
• Michigan Center of Medical Research — Clarkston, Michigan, United States
• Medical Dermatology Specialists — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.